Vitamin D receptor: A potential target for intervention

Urology

Volumn 60, Issue 3 SUPPL. 1, 2002, Pages 123-130

  Johnson, Candace S ^a,b   Hershberger, Pamela A ^a   Bernardi, Ronald J ^a   Mcguire, Terence F ^a   Trump, Donald L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ANTINEOPLASTIC AGENT; CALCITRIOL; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DEXAMETHASONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PACLITAXEL; PROTEIN P21; PROTEIN P27; VITAMIN D; VITAMIN D RECEPTOR;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METABOLISM; CANCER CELL; DRUG ACTIVITY; DRUG EFFECT; EPIDEMIOLOGICAL DATA; HYPERCALCEMIA; MAXIMUM TOLERATED DOSE; MINERAL METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA;

EID: 0036756356     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01591-1     Document Type: Article

References (79)

1. Bikle D.D., Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev. 14:1993;3-19.
2. Reichel H., Koeffler H.P., Norman A.W. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 320:1989;980-981.
3. McElwain M.C., Dettelbach M.A., Modzelewski R.A., et al. Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Diff. 3:1995;31-50.
4. Getzenberg R.H., Light B.W., Lapco P.E., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50:1997;999-1006.
5. Mangelsdorf D.J., Koeffler H.P., Donaldson C.A., et al. 1,25-Dihydroxyvitamin D3 induced differentiation in a human promyelocytic leukemia cell line HL-60 receptor mediated maturation to macrophage-like cells . J Cell Biol. 98:1984;391-398.
6. Colston K.W., Chander S.K., Mackay A.G., et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 44:1993;693-702.
7. Shabahang M., Buras R.R., Davoodi F., et al. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res. 54:1994;4057-4064.
8. 3 on primary cultures of human prostatic cells. Cancer Res. 54:1994;805-810.
9. 3-induced apoptosis of murine squamous cell carcinoma cells selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1 . J Biol Chem. 276:2001;26365-26373.
10. Zhou J.Y., Norman A.W., Chen D.L. 1,25-dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 87:1990;3929-3932.
11. Modzelewski R.A. Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Am Assoc Cancer Res. 40:1999;580.
12. Light B.W., Yu W.-D., McElwain M.C., et al. Potentiation of cisplatin anti-tumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 57:1997;3759-3764.
13. Kip1 in squamous cell carcinoma I response to 1,25-dihydroxycholecalciferol (calcitriol). Cancer Res. 59:1999;2644-2649.
14. Light B.W., Yu W.D., Shurin Z.R., et al. Potentiation of paclitaxel-mediated anti-tumor activity with 1,25-dihydroxycholecalciferol (calcitriol). Proc Am Assoc Cancer Res. 39:1998;308.
15. 3). Cancer Res. 7:2001;1043-1051.
16. Smith D.C., Johnson C.S., Freeman C.C., et al. A phase I trial of subcutaneous calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 5:1999;1339-1345.
17. 3 with dexamethasone enhances cell cycle arrest and apoptosis role of nuclear receptor cross-talk and Erk/Akt signaling . Clin Cancer Res. 12:2001;4164-4173.
18. Yu W.-D., McElwain M.C., Modzelewski R.A., et al. Potentiation of 1,25 dihydroxyvitamin D3-mediated anti-tumor activity with dexamethasone. J Natl Cancer Inst. 90:1998;134-141.
19. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10:1990;1307-1312.
20. Corder E.H., Guess H.A., Hulka B.S., et al. Vitamin D and prostate cancer a prediagnostic study with stored sera . Cancer Epidemiol Biomarkers Prev. 2:1993;467-472.
21. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1998;889-895.
22. Darwish H.M., DeLuca H.F. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol. 53:1996;321-344.
23. Christakos S., Raval-Pandya M., Wernyj R.P., et al. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J. 316:1996;361-371.
24. Darwish H., DeLuca H.F. Vitamin D-regulated gene expression. Crit Rev Eukaryot Gene Expr. 3:1993;89-116.
25. Studzinski G.P., McLane J.A., Uskokovic M.R. Signaling pathways for vitamin D-induced differentiation implications for therapy of proliferative and neoplastic diseases . Crit Rev Eukaryot Gene Expr. 3:1993;279-312.
26. Weigel N.L. Steroid hormone receptors and their regulation by phosphorylation. Biochem J. 319:1996;657-667.
27. Kuiper G.G.J.M., Brinkmann A.O. Steroid hormone receptor phosphorylation is there a physiological role? Mol Cell Endocrinol. 100:1994;103-107.
28. 2-Vitamin D3. A steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J Steroid Biochem Mol Biol. 41:1992;231-240.
29. Slater S.J., Kelly M.B., Taddeo F.J., et al. Direct activation of protein kinase C by 1α,25-Dihydroxyvitamin D3. J Biol Chem. 270:1995;6639-6643.
30. De Boland A.R., Morelli S., Boland R. 1,25-(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J Biol Chem. 269:1993;8675-8679.
31. 3 in CaCo-2 cells. Endocrinology. 135:1994;277-283.
32. de Boland A.R., Norman A.W. Evidence for involvement of protein kinase C and cyclic adenosine 3′,5′ monophosphate-dependent protein kinase in the 1,25-dihydroxyvitamin D3-mediated rapid stimulation of intestinal calcium transport (transcaltachia). Endocrinology. 127:1990;39-45.
33. 3 in normal human keratinocytes. J Invest Dermatol. 106:1996;1212-1217.
34. Frappart L., Falette N., Lefebvre M.F., et al. In vitro study of effects of 1,25-dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT 20 . Differentiation. 40:1989;63-69.
35. Shabahang M., Buras R.R., Davoodi F., et al. 1,25-dihydroxyvitamin D3 receptors as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53:1993;3712-3718.
36. Miller G.J., Stapleton G.E., Ferrara J.A., et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1,25-dihydroxyvitamin D3. Cancer Res. 52:1992;515-520.
37. Skowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines . Endocrinology. 132:1993;1952-1960.
38. de Vos S., Holden S., Heber D., et al. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate. 31:1997;77-83.
39. Godyn J.J., Xu H., Zhang F., et al. A dual block to cell cycle progression in HL-60 cells exposed to analogues of vitamin D3. Cell Prolif. 27:1994;37-46.
40. Rigby W.F., Noelle R.J., Krause K., et al. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation a cell cycle analysis . J Immunol. 135:1985;2279-2286.
41. Wang Q.M., Jones J.B., Studzinski G.P. Cyclin-dependent Kinase Inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 56:1996;264-267.
42. Liu M., Lee M.-H., Cohen M., et al. Transcriptional activation of the cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10:1996;142-153.
43. Biggs J.R., Kraft A.S. Inhibitors of cyclin-dependent kinase and cancer. J Mol Med. 73:1995;509-514.
44. 1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
45. WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 11:1995;1899-1905.
46. Henkart P.A. ICE family proteases mediators of all apoptotic cell death? Immunity. 4:1996;195-201.
47. Hockenbery D., Nunez G., Milliman C., et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond). 348:1990;334-336.
48. Hockenbery D.M. The bcl-2 oncogene and apoptosis. Semin Immunol. 4:1992;413-420.
49. Oltvai Z., Milliman C., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
50. Simboli-Campbell M., Narvaez C.J., Tenniswood M., et al. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 58:1996;367-376.
51. Elstner E., Linker-Israeli M., Umiel T., et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 56:1996;3570-3576.
52. Xu H.-M., Tepper C.G., Jones J.B., et al. 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Exp Cell Res. 209:1993;367-374.
53. Paul A., Wilson S., Belham C.M., et al. Stress-activated protein kinases activation, regulation and function . Cell Signal. 96:1997;403-410.
54. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res. 74:1998;49-139.
55. Strom M., Sandgren M.E., Brown T.A., et al. 1,25-Dihydroxyvitamin D3 up-regulates the 1,25-dihydroxyvitamin D3 receptor in vivo. Proc Natl Acad Sci U S A. 86:1989;9770-9773.
56. Chen T.L., Cone C.M., Morey-Holton E., et al. Glucocorticoid regulation of 1,25-(OH)2-vitamin D3 receptors in cultured mouse bone cells. J Biol Chem. 257:1982;13564-13569.
57. Levy J., Zuili I., Yankowitz N., et al. Induction of cytosolic receptors for 1,25-dihydroxyvitamin D3 in the immature rat uterus by estradiol. J Endocrinol. 100:1984;265-269.
58. Petkovich P.M., Heersche J.N.M., Tinker D.O., et al. Retinoic acid stimulates 1,25-dihydroxyvitamin D3 binding in rat osteosarcoma cells. J Biol Chem. 259:1984;8274-8280.
59. Reinhardt T.A., Horst R.L. Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrinology. 127:1990;942-948.
60. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 16:1995;200-257.
61. Hirst M., Feldman D. Glucocorticoid regulation of 1,25-(OH)2-vitamin D3 receptors divergent effects on mouse and rat intestine . Endocrinology. 111:1982;1400-1402.
62. Hirst M., Feldman D. Glucocorticoids down-regulate the number of 1,25-dihydroxyvitamin D3 receptors in mouse intestine. Biochem Biophys Res Comm. 105:1982;1590-1596.
63. Manolagas S.C., Abare J., Deftos L.J. Glucocorticoids increase the 1,25-(OH)2 D3 receptor concentration in rat osteogenic sarcoma cells. Calcif Tissue Int. 36:1982;153-157.
64. Kimberg D.V., Baerg R.D., Gershon E., et al. Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest. 50:1971;1309-1321.
65. Haynes R.C. Agents affecting calcification calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds . Gilman A.G., Rall T.W., Nies A.S., et al. The Pharmacological Basis of Therapeutics. 1990;1496-1501 Pergamon Press, New York.
66. Barloule M., Chadebech P., Baldin V., et al. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene. 15:1997;2867-2875.
67. Stewart Z.A., Mays D., Pietenpol J.A. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 59:1999;3831-3837.
68. Tsuruoka S., Sugimoto K., Ohmori M., et al. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism a single-dose study . Clin Pharmacol Ther. 1999;609-616.
69. Maung H.M., Elangovan L., Frazao J.M., et al. Efficacy and and side effects of intermittent intravenous and oral doxercalciferol (1 alpha-hydroxyvitamin D(2)) in dialysis paients with secondary hyperparathyroidism a sequential comparison . Am J Kidney Dis. 37:2001;532-543.
70. Cunningham D., Gilchrist N.L., Cowan R.A., et al. Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. BMJ. 291:1985;1153-1155.
71. Koeffler H.P., Hirji K., Iltri L., et al. 1,25-Dihydroxyvitamin D3 in vivo and in vitro effects on human preleukemic and leukemic cells . Cancer Treat Rep. 69:1985;1399-1407.
72. Rolla D., Paoletti E., Marsano L., et al. Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int. 13:1993;118-121.
73. Davies M. High-dose vitamin D therapy indications, benefits and hazards . Walter P., Brubacher G., Stahelin H., Elevated Dosages of Vitamins. 1989;81-86 Hans Huber, Lewistown, NY.
74. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. J Clin Oncol. 17:1999;2506-2513.
75. Tannock I., Gospodarowicz M., Meakin W., et al. Treatment of metastatic prostatic cancer with low-dose prednisone evaluation of pain and quality of life as pragmatic indices of response . J Clin Oncol. 7:1989;590-597.
76. Small E.J., Meyer M., Marshall M.E., et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone . J Clin Oncol. 18:2000;1440-1450.
77. Weitzman A.L., Sneton G., Zuech N., et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol. 163:2000;834-837.
78. 3) on the pharmacokinetics of paclitaxel or carboplatin results of two phase I studies . [abstract] Ann Oncol. 19:2000;210a.
79. 3) and dexamethasone in androgen independent prostate cancer (AIPC). [abstract] Ann Oncol. 12:2000;337a.